Chiasma (NASDAQ:CHMA) PT Set at $18.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $18.00 price objective on Chiasma (NASDAQ:CHMA) in a report issued on Friday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other analysts have also recently issued reports about the company. HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Chiasma in a report on Tuesday, July 23rd. Piper Jaffray Companies assumed coverage on Chiasma in a report on Wednesday, July 31st. They set an overweight rating and a $11.00 price objective for the company. Brookline Capital Management reissued a buy rating on shares of Chiasma in a report on Wednesday, July 24th. ValuEngine cut Chiasma from a buy rating to a hold rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut Chiasma from a buy rating to a hold rating in a report on Thursday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $12.35.

Shares of Chiasma stock traded up $0.03 during trading on Friday, reaching $5.25. The company’s stock had a trading volume of 21,604 shares, compared to its average volume of 377,214. The stock has a 50-day moving average price of $5.19 and a two-hundred day moving average price of $6.08. Chiasma has a one year low of $2.11 and a one year high of $9.25. The stock has a market capitalization of $219.85 million, a P/E ratio of -4.10 and a beta of 1.19.

Chiasma (NASDAQ:CHMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. Sell-side analysts forecast that Chiasma will post -1.09 EPS for the current fiscal year.

In other news, Director Roni Mamluk sold 10,000 shares of the business’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $6.35, for a total transaction of $63,500.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $63,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Scott Minick bought 9,818 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average price of $5.19 per share, with a total value of $50,955.42. Following the completion of the transaction, the director now directly owns 62,531 shares in the company, valued at approximately $324,535.89. The disclosure for this purchase can be found here. Insiders own 8.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Quantitative Systematic Strategies LLC acquired a new position in shares of Chiasma during the 2nd quarter worth about $100,000. Cubist Systematic Strategies LLC grew its position in shares of Chiasma by 35.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,722 shares during the period. Citadel Advisors LLC acquired a new position in shares of Chiasma during the 2nd quarter worth about $145,000. Invesco Ltd. acquired a new position in shares of Chiasma during the 2nd quarter worth about $186,000. Finally, Wells Fargo & Company MN acquired a new position in shares of Chiasma during the 2nd quarter worth about $237,000. Institutional investors own 52.97% of the company’s stock.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Further Reading: Golden Cross

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.